R&D Trends

NCI, CRUK, Wellcome partner on cancer models to accelerate research

Monday, July 11, 2016

An international project to develop a large, globally accessible bank of new cancer cell culture models for the research community has launched. The National Cancer Institute (NCI), part of the NIH; Cancer Research U.K., London; the Wellcome Trust Sanger Institute, Cambridge, England; and the foundation Hubrecht Organoid Technology, Utrecht, Netherlands, are joining forces to develop the Human Cancer Models Initiative (HCMI), which will bring together expertise from around the world to make about 1,000 cancer cell models.

[Read More]

NIH awards $55M to build million-person precision medicine study

Thursday, July 7, 2016

The NIH has announced $55 million in awards in fiscal year 2016 to build the foundational partnerships and infrastructure needed to launch the Cohort Program of President Obama’s Precision Medicine Initiative (PMI). The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve our ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics.

[Read More]

Takeda, Altos Therapeutics partner for the treatment of gastroparesis

Tuesday, July 5, 2016

Takeda Pharmaceutical and Altos Therapeutics have entered into a definitive agreement to further the development of Altos’ proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing phase I studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.

[Read More]

Four NCI Cancer Centers form Consortium, collaborate with Celgene

Tuesday, June 28, 2016

The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.

[Read More]